Pasar al contenido principal

CARACTERIZACION DE LA FUNCION Y POTENCIAL TERAPEUTICO DE LOS COMPLEJOS DE KRAS EN MEMBRANA

PID2020-116824RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Experimental variables determine the outcome of RAS-RAS interactions

  • Zhou, Zhiwei
  • Nguyen, Tra Ly
  • Li, Xingxiao
  • Poujol, Christel
  • Berlinska, Ewa
  • Vietti Michelina, Sandra
  • Kapp, Jonas N.
  • Plückthun, Andreas
  • Winslow, Monte M.
  • Ambrogio, Chiara
  • Shan, Yibing
  • Santamaria, David
  • Westover, Kenneth D.
RAS clustering at the cell membrane is critical to activate signaling in cells, but whether this clustering is mediated exclusively by its c-terminal hypervariable region, receives contributions from the G-domain of RAS, and/or is influenced by secondary effectors has been intensely debated. Reports that G-domain mutations do not modulate RAS-RAS interactions have led some to question the validity of previous experiments that indicate the G-domain plays a role in RAS clustering/interactions. Here we reconcile these findings by clarifying the impact of experimental variables, such as protein expression levels, cellular context, RAS zygosity, and secondary effector interactions on RAS clustering. Lack of control over these variables impacts the results using G-domain mutations across various assay systems and can lead to unsound conclusions., This work was supported by CPRIT RP220145 and NIH R01CA244341 to KDW, NIH R01-CA230025 to MMW, Antidote Health Foundation for Cure of Cancer to YS, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. [101001288]) and AIRC under IG 2021 - ID. 25737 project (to C.A.), the Ministerio de Ciencia e Innovación (Retos PID2020–116824RB-I00) and Institut National du Cancer (INCA_13911) to DS, and Swiss Cancer Research foundation to AP (KFS 4147–02–2017 and KFS-5290–02–2021-R)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma

  • Nokin, Marie-Julie
  • Darbo, Elodie
  • Richard, Elodie
  • San José, Sonia
  • Hita, Sergio de
  • Prouzet-Mauleon, Valérie
  • Turcq, Béatrice
  • Gerardelli, Laura
  • Crake, Rebekah
  • Velasco, Valérie
  • Koopmansch, Benjamin
  • Lambert, Frederic
  • Xue, Jenny Y.
  • Sang, Ben
  • Horne, Julie
  • Ziemons, Eric
  • Villanueva, Alberto
  • Blomme, Arnaud
  • Herfs, Michael
  • Cataldo, Didier
  • Calvayrac, Olivier
  • Porporato, Paolo
  • Nadal, Ernest
  • Lito, Piro
  • Jänne, Pasi A.
  • Ricciuti, Biagio
  • Awad, Mark M.
  • Ambrogio, Chiara
  • Santamaria, David
The current targeted therapy for BRAFV600E-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This regimen extends survival when compared to single-agent treatments, but disease progression is unavoidable. By using whole-genome CRISPR screening and RNA sequencing, we characterize the vulnerabilities of both persister and D/T-resistant cellular models. Oxidative stress together with concomitant induction of antioxidant responses is boosted by D/T treatment. However, the nature of the oxidative damage, the choice of redox detoxification systems, and the resulting therapeutic vulnerabilities display stage-specific differences. Persister cells suffer from lipid peroxidation and are sensitive to ferroptosis upon GPX4 inhibition in vivo. Biomarkers of lipid peroxidation are detected in clinical samples following D/T treatment. Acquired alterations leading to mitogen-activated protein kinase (MAPK) reactivation enhance cystine transport to boost GPX4-independent antioxidant responses. Similarly to BRAFV600E-mutant melanoma, histone deacetylase (HDAC) inhibitors decrease D/T-resistant cell viability and extend therapeutic response in vivo., Research in D.S. laboratory was funded by Siric-BRIO (Bordeaux Recherche Intégrée en Cancérologie, INCa convention 2018-006 and INSERM convention 18CI05500) and a Senior Chair Idex-Université de Bordeaux (2016-0396) and grants from Institut National Du Cancer (INCA_13911), Ministerio de Ciencia e Innovación (Retos PID2020-116824RB-I00), and by AECC Excellence Program 2022 (EPAEC222641CICS). M.-J.N. was supported by postdoctoral fellowships from Fondation ARC pour la recherche contre le cancer and from FNRS-Télévie. This work was also supported by the Fund André Daners, managed by the King Baudouin Foundation and by the Foundation Leon Fredericq. A.V. received funding from ISCIII (grant PI22-00548, co-funded by FEDER). E.N. received funding from ISCIII (grant PI21/00789, co-funded by FEDER). C.A. received funding by the Giovanni Armenise-Harvard Foundation, the Italian Ministry of University and Research (FARE-R207ENY9KZ), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant 101001288), and AIRC under IG 2021-ID. 25737 project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

  • Nokin, Marie-Julie
  • Mira, Alessia
  • Patrucco, Enrico
  • Ricciuti, Biagio
  • Cousin, Sophie
  • Soubeyran, Isabelle
  • San José, Sonia
  • Peirone, Serena
  • Caizzi, Livia
  • Vietti Michelina, Sandra
  • Bourdon, Aurelien
  • Wang, Xinan
  • Daniel Alvarez-Villanueva, Daniel
  • Martínez-Iniesta, María
  • Vidal, August
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Awad, Mark M.
  • Nadal, Ernest
  • Villanueva, Alberto
  • Italiano, Antoine
  • Cereda, Matteo
  • Santamaria, David
  • Ambrogio, Chiara
Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer. Drug treatment imposes selective pressures leading to the outgrowth of drug-resistant variants. Mass sequencing from patients’ biopsies identified a number of acquired KRAS mutations -both in cis and in trans- in resistant tumors. We demonstrate here that disease progression in vivo can also occur due to adaptive mechanisms and increased KRAS-GTP loading. Using the preclinical tool tri-complex KRASG12C-selective covalent inhibitor, RMC-4998 (also known as RM-029), that targets the active GTP-bound (ON) state of the oncogene, we provide a proof-of-concept that the clinical stage KRASG12C(ON) inhibitor RMC-6291 alone or in combination with KRASG12C(OFF) drugs can be an alternative potential therapeutic strategy to circumvent resistance due to increased KRAS-GTP loading., This work was funded by grants from Institut National du Cancer (grant No. INCA_13911), SIRIC-BRIO (Bordeaux Recherche Intégrée en Cancérologie, INCa convention 2018-006 & INSERM convention 18CI05500), the French government in the framework of the Investments for the Future program IdEx-Université de Bordeaux, Ministerio de Ciencia e Innovación (PID2020-116824RB-I00) and Scientific Foundation of the Spanish Association Against Cancer (EPAEC222641CICS and PRYGN222960SANT) (to D.S.), the Giovanni Armenise–Harvard Foundation, the Italian Ministry of University and Research (FARE-R207ENY9KZ), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. [101001288]), AIRC under IG 2021—ID. 25737 project and Revolution Medicines under a sponsored research agreement (to C.A.), Instituto de Salud Carlos III (grant PI21/00789) (co-funded by European Regional Development Fund, ERDF, a way to build Europe) (to E.N.) and two grants from the Spanish Ministry of Economy and Competitiveness - Instituto de Salud Carlos III FEDER (PI21/00789 and FIS PI22-00548), Generalitat de Catalunya 2021SGR00184 (to E.N. and A.V., respectively). M.J.N. was supported by a bourse d’excellence de la Fédération Wallonie-Bruxelles (WBI) and a postdoctoral fellowship from Foundation ARC pour la recherche contre le cancer. B.R. was supported by the Barbara Gomez Endowed Advanced Program in Thoracic Oncology. D.A.-V. held a PFIS predoctoral fellowship (FI20/00130) from Instituto de Salud Carlos III. M.C. is supported by AIRC under MFAG 2017—ID. 20566 and BRIDGE 2023—ID. 28739 projects and the Compagnia di San Paolo Foundation. C.A. is supported by the Zanon di Valgiurata family through Justus s.s., Peer reviewed